Etilefrine, sold under the brand name Effortil among others, is a sympathomimetic medication used as an antihypotensive agent to treat orthostatic hypotension. It is usually used by mouth, but is also available as an injectable. Side effects of etilefrine + some more technical info Etilefrine is a phenylethanolamine derivative with mixed alpha1 and beta1 adrenergic agonist activity that raises vascular tone and cardiac output to restore and maintain blood pressure in symptomatic hypotension. Typical adult oral dosing is in the low milligram range with repeat administration two to three times daily depending on clinical response and tolerability; parenteral formulations are reserved for acute or monitored settings. After absorption etilefrine undergoes hepatic metabolism and renal excretion of parent and metabolites; plasma half life is short to moderate requiring repeated dosing for sustained effect. Relevant monitoring includes blood pressure, heart rate, and signs of ischemia in patients with cardiovascular disease. Clinically observed adverse reactions include palpitations, headache, hypertension, tachycardia, and less commonly arrhythmias or exacerbation of angina. Use is contraindicated or requires caution in patients with uncontrolled hypertension, severe organic heart disease, pheochromocytoma, and certain hyperthyroid states. Drug interactions that potentiate pressor effects or alter heart rate should be reviewed before initiation.
Parent: Etilefrine
Parent: Etilefrine / Etilefrine Hydrochloride
For pharmaceutical quality control the active substance is characterized and controlled for specified related compounds and unspecified impurities using validated chromatographic methods. Common related substances include N-deethylated analogs, oxidative products of the phenolic ring, deamination products and trace solvent residues stemming from synthesis. Typical manufacturer and monograph acceptance criteria are in the low parts per thousand to parts per ten thousand range, for example individual specified impurities often limited to about 0.1 to 0.3 percent and total impurities commonly limited to about 0.5 to 1.0 percent, while genotoxic or unidentified impurities are controlled to tighter limits in accordance with regulatory guidance. Exact impurity profiles and limits vary with the pharmacopoeial monograph and supplier batch specifications and should be confirmed on the certificate of analysis for each API lot.
Etilefrine is used to treat symptomatic low blood pressure, most commonly orthostatic hypotension, by increasing vascular resistance and supporting cardiac output. It can be administered orally for chronic management or by injection in acute or monitored clinical situations.
Etilefrine hydrochloride acts as a sympathomimetic agent with predominant alpha1 adrenergic receptor agonism and ancillary beta1 receptor activity. Activation of alpha1 receptors on vascular smooth muscle causes vasoconstriction and increased peripheral resistance while beta1 stimulation increases heart rate and myocardial contractility, together producing a rise in arterial pressure.
Common side effects include headache, palpitations, increased blood pressure, and tachycardia. Less frequent adverse events can include arrhythmias, anxiety, anorexia, nausea, and worsening of ischemic heart disease. Adverse effects are dose related and patients with cardiovascular disease require close monitoring.
